BRIEF—ImmuneID names Jessica Atkinson as CBO

US biopharma company ImmuneID has appointed Jessica Atkinson as chief business officer.

She will oversee business activities as part of ImmuneID leadership with dual goals of advising on the company’s current direction and exploring and maximizing external collaboration opportunities for its aiSPIRE platform.

“Jessica is a leader in the field, with expertise in developing and executing on portfolio-advancing strategies and transactions with the potential to shape the patient treatment landscape,” said Jim Scibetta, chief executive at ImmuneID.

“We are excited to have her flexible and strategic perspective assist ImmuneID in drawing connections between a wide range of scientific concepts and applications, enabling us to develop therapeutic and biomarker development strategies across a spectrum of indications and therapeutic modalities,” he added.

Ms Atkinson joins ImmuneID from Glympse Bio, where she was the senior vice president of business development, crafting and leading the execution of business development strategy for a newly discovered, completely novel technology.

Prior to Glympse, she managed an oncology therapeutics market-based business development strategy at Foundation Medicine Inc.